Cognitive-impairing effects of medroxyprogesterone acetate in the rat

Independent and interactive effects across time

Brittany Braden, Alexandra N. Garcia, Sarah E. Mennenga, Laszlo Prokai, Stephanie R. Villa, Jazmin I. Acosta, Natalie Lefort, Alain R. Simard, Heather Bimonte-Nelson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Rationale: The synthetic progestin medroxyprogesterone acetate (MPA), widely used in hormone therapy (HT) and as the contraceptive Depo Provera, is implicated in detrimental cognitive effects in women. Recent evidence in aged ovariectomized (Ovx) rodents shows that short-term MPA treatment impairs cognition and alters the GABAergic system. Objectives: Using rats, we evaluated the long-lasting cognitive and GABAergic effects of MPA administered in young adulthood (Early-MPA), modeling contraception, and how this early exposure interacts with later MPA treatment (Late-MPA), modeling HT. Methods: Early-MPA treatment involved weekly anti-ovulatory MPA injections (3.5 mg) from 4 to 8 months of age in ovary-intact rats. At 10 months old, rats were Ovx and weekly MPA injections were re-initiated and continued throughout testing for Late-MPA treatment. Results: On the water radial-arm maze, all MPA-treated groups showed working memory impairment compared to Controls (p<0.05); Early+Late-MPA rats were impaired on multiple dimensions of working memory (p<0.05). On the Morris maze, Late-MPA rats showed greater overnight forgetting compared to Controls (p<0.05). At study conclusion, MPA was detected in serum in all MPA-treated groups except Early-MPA, confirming treatment and clearance from serum in Early-MPA rats. In animals with detectable serum MPA, higher MPA levels were associated with less dorsal-hippocampal glutamic acid decarboxylase, the synthesizing enzyme for GABA (p=0.0059). Conclusions: Findings suggest that MPA treatment leads to long-lasting cognitive impairments in the rodent, even in the absence of circulating MPA in animals given prior MPA treatment, which may relate to the GABAergic system. Further research defining the parameters of the negative impact of this widely used progestin on brain and cognition is warranted.

Original languageEnglish (US)
Pages (from-to)405-418
Number of pages14
JournalPsychopharmacology
Volume218
Issue number2
DOIs
StatePublished - Nov 2011

Fingerprint

Medroxyprogesterone Acetate
Therapeutics
Short-Term Memory
Cognition
Rodentia
Serum
GABA Agents
Progesterone Congeners
Hormones
Injections
Glutamate Decarboxylase

Keywords

  • Aging
  • Cognition
  • Contraceptive
  • Hormone therapy
  • Learning and memory
  • Menopause
  • Progestins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cognitive-impairing effects of medroxyprogesterone acetate in the rat : Independent and interactive effects across time. / Braden, Brittany; Garcia, Alexandra N.; Mennenga, Sarah E.; Prokai, Laszlo; Villa, Stephanie R.; Acosta, Jazmin I.; Lefort, Natalie; Simard, Alain R.; Bimonte-Nelson, Heather.

In: Psychopharmacology, Vol. 218, No. 2, 11.2011, p. 405-418.

Research output: Contribution to journalArticle

Braden, Brittany ; Garcia, Alexandra N. ; Mennenga, Sarah E. ; Prokai, Laszlo ; Villa, Stephanie R. ; Acosta, Jazmin I. ; Lefort, Natalie ; Simard, Alain R. ; Bimonte-Nelson, Heather. / Cognitive-impairing effects of medroxyprogesterone acetate in the rat : Independent and interactive effects across time. In: Psychopharmacology. 2011 ; Vol. 218, No. 2. pp. 405-418.
@article{acd76c577ede43c9bb8eeac3d48256f2,
title = "Cognitive-impairing effects of medroxyprogesterone acetate in the rat: Independent and interactive effects across time",
abstract = "Rationale: The synthetic progestin medroxyprogesterone acetate (MPA), widely used in hormone therapy (HT) and as the contraceptive Depo Provera, is implicated in detrimental cognitive effects in women. Recent evidence in aged ovariectomized (Ovx) rodents shows that short-term MPA treatment impairs cognition and alters the GABAergic system. Objectives: Using rats, we evaluated the long-lasting cognitive and GABAergic effects of MPA administered in young adulthood (Early-MPA), modeling contraception, and how this early exposure interacts with later MPA treatment (Late-MPA), modeling HT. Methods: Early-MPA treatment involved weekly anti-ovulatory MPA injections (3.5 mg) from 4 to 8 months of age in ovary-intact rats. At 10 months old, rats were Ovx and weekly MPA injections were re-initiated and continued throughout testing for Late-MPA treatment. Results: On the water radial-arm maze, all MPA-treated groups showed working memory impairment compared to Controls (p<0.05); Early+Late-MPA rats were impaired on multiple dimensions of working memory (p<0.05). On the Morris maze, Late-MPA rats showed greater overnight forgetting compared to Controls (p<0.05). At study conclusion, MPA was detected in serum in all MPA-treated groups except Early-MPA, confirming treatment and clearance from serum in Early-MPA rats. In animals with detectable serum MPA, higher MPA levels were associated with less dorsal-hippocampal glutamic acid decarboxylase, the synthesizing enzyme for GABA (p=0.0059). Conclusions: Findings suggest that MPA treatment leads to long-lasting cognitive impairments in the rodent, even in the absence of circulating MPA in animals given prior MPA treatment, which may relate to the GABAergic system. Further research defining the parameters of the negative impact of this widely used progestin on brain and cognition is warranted.",
keywords = "Aging, Cognition, Contraceptive, Hormone therapy, Learning and memory, Menopause, Progestins",
author = "Brittany Braden and Garcia, {Alexandra N.} and Mennenga, {Sarah E.} and Laszlo Prokai and Villa, {Stephanie R.} and Acosta, {Jazmin I.} and Natalie Lefort and Simard, {Alain R.} and Heather Bimonte-Nelson",
year = "2011",
month = "11",
doi = "10.1007/s00213-011-2322-4",
language = "English (US)",
volume = "218",
pages = "405--418",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Cognitive-impairing effects of medroxyprogesterone acetate in the rat

T2 - Independent and interactive effects across time

AU - Braden, Brittany

AU - Garcia, Alexandra N.

AU - Mennenga, Sarah E.

AU - Prokai, Laszlo

AU - Villa, Stephanie R.

AU - Acosta, Jazmin I.

AU - Lefort, Natalie

AU - Simard, Alain R.

AU - Bimonte-Nelson, Heather

PY - 2011/11

Y1 - 2011/11

N2 - Rationale: The synthetic progestin medroxyprogesterone acetate (MPA), widely used in hormone therapy (HT) and as the contraceptive Depo Provera, is implicated in detrimental cognitive effects in women. Recent evidence in aged ovariectomized (Ovx) rodents shows that short-term MPA treatment impairs cognition and alters the GABAergic system. Objectives: Using rats, we evaluated the long-lasting cognitive and GABAergic effects of MPA administered in young adulthood (Early-MPA), modeling contraception, and how this early exposure interacts with later MPA treatment (Late-MPA), modeling HT. Methods: Early-MPA treatment involved weekly anti-ovulatory MPA injections (3.5 mg) from 4 to 8 months of age in ovary-intact rats. At 10 months old, rats were Ovx and weekly MPA injections were re-initiated and continued throughout testing for Late-MPA treatment. Results: On the water radial-arm maze, all MPA-treated groups showed working memory impairment compared to Controls (p<0.05); Early+Late-MPA rats were impaired on multiple dimensions of working memory (p<0.05). On the Morris maze, Late-MPA rats showed greater overnight forgetting compared to Controls (p<0.05). At study conclusion, MPA was detected in serum in all MPA-treated groups except Early-MPA, confirming treatment and clearance from serum in Early-MPA rats. In animals with detectable serum MPA, higher MPA levels were associated with less dorsal-hippocampal glutamic acid decarboxylase, the synthesizing enzyme for GABA (p=0.0059). Conclusions: Findings suggest that MPA treatment leads to long-lasting cognitive impairments in the rodent, even in the absence of circulating MPA in animals given prior MPA treatment, which may relate to the GABAergic system. Further research defining the parameters of the negative impact of this widely used progestin on brain and cognition is warranted.

AB - Rationale: The synthetic progestin medroxyprogesterone acetate (MPA), widely used in hormone therapy (HT) and as the contraceptive Depo Provera, is implicated in detrimental cognitive effects in women. Recent evidence in aged ovariectomized (Ovx) rodents shows that short-term MPA treatment impairs cognition and alters the GABAergic system. Objectives: Using rats, we evaluated the long-lasting cognitive and GABAergic effects of MPA administered in young adulthood (Early-MPA), modeling contraception, and how this early exposure interacts with later MPA treatment (Late-MPA), modeling HT. Methods: Early-MPA treatment involved weekly anti-ovulatory MPA injections (3.5 mg) from 4 to 8 months of age in ovary-intact rats. At 10 months old, rats were Ovx and weekly MPA injections were re-initiated and continued throughout testing for Late-MPA treatment. Results: On the water radial-arm maze, all MPA-treated groups showed working memory impairment compared to Controls (p<0.05); Early+Late-MPA rats were impaired on multiple dimensions of working memory (p<0.05). On the Morris maze, Late-MPA rats showed greater overnight forgetting compared to Controls (p<0.05). At study conclusion, MPA was detected in serum in all MPA-treated groups except Early-MPA, confirming treatment and clearance from serum in Early-MPA rats. In animals with detectable serum MPA, higher MPA levels were associated with less dorsal-hippocampal glutamic acid decarboxylase, the synthesizing enzyme for GABA (p=0.0059). Conclusions: Findings suggest that MPA treatment leads to long-lasting cognitive impairments in the rodent, even in the absence of circulating MPA in animals given prior MPA treatment, which may relate to the GABAergic system. Further research defining the parameters of the negative impact of this widely used progestin on brain and cognition is warranted.

KW - Aging

KW - Cognition

KW - Contraceptive

KW - Hormone therapy

KW - Learning and memory

KW - Menopause

KW - Progestins

UR - http://www.scopus.com/inward/record.url?scp=82955233596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955233596&partnerID=8YFLogxK

U2 - 10.1007/s00213-011-2322-4

DO - 10.1007/s00213-011-2322-4

M3 - Article

VL - 218

SP - 405

EP - 418

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -